Nuevocor
Singapore’s Nuevocor raises $45M Series B for Novel Cardiomyopathy therapy development
Nuevocor, a Singapore-headquartered IND-stage biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, has announced the successful completion of $45 million Series B financing.
